Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 4:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: stem cells Clear all
Completed Phase 1 Interventional

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

NCT00968760
View directory record Official record
Conditions
Lymphoma, B-cell Lymphoma
Interventions
Leukapheresis, Stem Cell Transplant, CD19-specific T Cell Infusion, IL-2, Carmustine, Etoposide, Cytarabine, Melphalan
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 8, 2026, 4:43 PM EDT
No Longer Available No phase listed Expanded access

Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer

NCT04087889
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences LLC
Industry
Eligibility
Male only
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 8, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation

NCT01203020
View directory record Official record
Conditions
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Busulfan, Fludarabine
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Sep 8, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)

NCT00912223
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Hematopoietic Stem Cell Transplant
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
21
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Sep 8, 2026, 4:43 PM EDT
Active, not recruiting Phase 2 Interventional

Autologous Adipose Derived Mesenchymal Stem Cells for Spinal Cord Injury Patients

NCT04520373
View directory record Official record
Conditions
Spinal Cord Injuries, Paralysis
Interventions
Best Medical Management: Occupational and Physical Therapy, Autologous, Adipose Derived Mesenchymal Stem Cells
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 8, 2026, 4:43 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Defining the Role of the Gut Microbiome in Mediating the Effects of Obesity on Intestinal Stem Cells

NCT02863029
View directory record Official record
Conditions
Obesity
Interventions
Flexible Sigmoidoscopy
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Sep 8, 2026, 4:43 PM EDT
Terminated Phase 2 Interventional Results available

Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

NCT03044353
View directory record Official record
Conditions
Amyloidosis
Interventions
GSK2315698 (CPHPC), GSK2398852 (anti-SAP mAb)
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Sep 8, 2026, 4:43 PM EDT
Completed Phase 2 Interventional

Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)

NCT02633163
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Low Dose Mesenchymal Stem Cells (MSCs), High Dose Mesenchymal Stem Cells (MSCs), Placebo Infusion
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 8, 2026, 4:43 PM EDT
Withdrawn Phase 1 Interventional

Hematopoietic Stem Cell Transplantation in Patients With Antiphospholipid Syndrome

NCT00278616
View directory record Official record
Conditions
ANTIPHOSPHOLIPID SYNDROME
Interventions
Stem Cell Transplantation
Biological
Lead sponsor
Richard Burt, MD
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Sep 8, 2026, 4:43 PM EDT
Not listed Phase 1 Interventional

Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)

NCT02293603
View directory record Official record
Conditions
Dilated Cardiomyopathy (DCM), Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy, Heart Failure
Interventions
Allogeneic Cardiosphere-Derived Cells (CDCs)
Biological
Lead sponsor
Capricor Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Sep 8, 2026, 4:43 PM EDT
Terminated Phase 2Phase 3 Interventional

Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)

NCT00038805
View directory record Official record
Conditions
Leukemia
Interventions
Mylotarg
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
55 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 8, 2026, 4:43 PM EDT
Recruiting Phase 2 Interventional

BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)

NCT04187105
View directory record Official record
Conditions
Acute Leukemia, MDS
Interventions
Conditioning regimen with half-matched (haploidentical) stem cell transplant, Conditioning regimen with half-matched (haploidentical) stem cell transplant, Conditioning regimen with half-matched (haploidentical) stem cell transplant, Conditioning regimen with half-matched (haploidentical) stem cell transplant
Radiation · Drug · Device + 1 more
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 8, 2026, 4:43 PM EDT
Withdrawn Phase 1 Interventional

Umbilical Cord Blood in the Treatment of Stroke in Children.

NCT01700166
View directory record Official record
Conditions
Arterial Ischemic Stroke (AIS) in Children
Interventions
Autologous Human Cord Blood derived Stem Cell injection
Biological
Lead sponsor
Aryn Knight
Other
Eligibility
6 Weeks to 6 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 8, 2026, 4:43 PM EDT
Terminated Phase 2 Interventional

Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma

NCT00141700
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin's
Interventions
Rituximab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 9, 2008 · Synced Sep 8, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

NCT01437709
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Ofatumumab (This arm is closed), Ofatumumab + Bendamustine
Biological · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 8, 2026, 4:43 PM EDT
Terminated No phase listed Observational

Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors

NCT00710151
View directory record Official record
Conditions
Primary Central Nervous System Lymphoma (PCNSL)
Interventions
Not listed
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 8, 2026, 4:43 PM EDT
Terminated Phase 2 Interventional Results available

T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases

NCT00589602
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Secondary Myelofibrosis
Interventions
peripheral blood lymphocyte therapy, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation (TBI)
Procedure · Radiation
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 8, 2026, 4:43 PM EDT
Completed Phase 1 Interventional

Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant

NCT00107354
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
aldesleukin, therapeutic allogeneic lymphocytes, therapeutic autologous lymphocytes, cytarabine, etoposide, mitoxantrone hydrochloride, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
14 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2010 · Synced Sep 8, 2026, 4:43 PM EDT
Not listed Phase 2 Interventional

Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse

NCT00069966
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, cisplatin, cytarabine, methylprednisolone, pixantrone dimaleate, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Theradex
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
28
States / cities
Tucson, Arizona • Duarte, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2009 · Synced Sep 8, 2026, 4:43 PM EDT
Completed Phase 2 Interventional

Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma

NCT00005631
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, carboplatin, etoposide, ifosfamide
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 72 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 8, 2026, 4:43 PM EDT
Completed No phase listed Observational Results available

Autologous Stem Cell Treatment for Chronic Lung Disease Study

NCT03044431
View directory record Official record
Conditions
COPD, Interstitial Lung Disease
Interventions
Cell therapy
Procedure
Lead sponsor
Lung Institute
Industry
Eligibility
16 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Sep 8, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma

NCT01453101
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Fludarabine monophosphate, melphalan, Bortezomib
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 69 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 8, 2026, 4:43 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Ocular Complications From Cancer Therapy - Patient Registry and Biobank

NCT06874283
View directory record Official record
Conditions
Graft Versus Host Disease in Eye, Ocular Complications, Inflammatory Dry Eye Disease
Interventions
Eye exam
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 8, 2026, 4:43 PM EDT
Completed No phase listed Observational

Outcomes Data of Bone Marrow Stem Cells to Treat Hip and Knee Osteoarthritis

NCT01601951
View directory record Official record
Conditions
Hip and Knee Osteoarthritis
Interventions
Procedural, Bone Marrow concentrate injection
Other
Lead sponsor
Regenerative Pain Center, Illinois
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Des Plaines, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Sep 8, 2026, 4:43 PM EDT